Alzamend Neuro Inc.
Organization details
- Legal name
- Alzamend Neuro Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Atlanta
- Headquarters state / province
- Georgia
- Headquarters country
- United States
- Fiscal year end
- April
- Ticker symbol
- ALZN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001677077
- EIN
- 81-1822909
Board of directors
-
Henry Carl Nisser · Director · EVP and General CounselSince 2026
-
Jeffrey Oram · DirectorSince 2026
-
Lynne Fahey McGrath · DirectorSince 2023
-
Mark Gustafson · DirectorSince 2026
-
Milton C. Ault III · DirectorSince 2024
-
Stephan Jackman · Director · Chief Executive OfficerSince 2023
-
William B. Horne · DirectorSince 2023
Chief executives
Director election results
Annual meeting of April 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.3%
-
84.4%
-
84.4%
-
84.7%
-
85.2%
-
85.4%
-
85.4%
Board connections
3 of this board's directors also sit on 3 other boards.
- via Henry Carl Nisser, Milton C. Ault III and William B. Horne
- via Henry Carl Nisser and Milton C. Ault III
- via Henry Carl Nisser and Milton C. Ault III
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $108,388
- 1 purchase by 1 insider
- Sold, last 12 months
- $14,018
- 3 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 26, 2026 | Milton C. Ault III Director | Open-market sale | −2,000 | $1.56 | $3,120 |
| Apr 14, 2026 | Milton C. Ault III Director | Open-market purchase | +108,388 | $1.00 | $108,388 |
| Dec 23, 2025 | Milton C. Ault III Director | Open-market sale | −1,851 | $2.07 | $3,832 |
| Dec 19, 2025 | William B. Horne Director | Open-market sale | −3,333 | $2.12 | $7,066 |
| Oct 23, 2025 | Lynne Fahey McGrath Director | Open-market sale | −30 | $2.29 | $69 |
| Oct 9, 2025 | Milton C. Ault III Director | Open-market sale | −20,397 | $2.32 | $47,321 |
| Oct 8, 2025 | Milton C. Ault III Director | Derivative conversion | +61,743 | $2.32 | $143,244 |
| Oct 8, 2025 | Milton C. Ault III Director | Open-market sale | −101,394 | $2.44 | $247,401 |
| Oct 7, 2025 | Milton C. Ault III Director | Derivative conversion | +100,000 | $2.32 | $232,000 |
| Oct 7, 2025 | Milton C. Ault III Director | Open-market sale | −57,379 | $2.49 | $142,874 |
| Oct 6, 2025 | Milton C. Ault III Director | Open-market sale | −82,033 | $2.45 | $200,981 |
| Oct 3, 2025 | Milton C. Ault III Director | Derivative conversion | +100,000 | $2.32 | $232,000 |
| Oct 3, 2025 | Milton C. Ault III Director | Open-market sale | −65,903 | $2.44 | $160,803 |
| Oct 2, 2025 | Milton C. Ault III Director | Open-market sale | −20,686 | $2.39 | $49,440 |
| Oct 1, 2025 | Milton C. Ault III Director | Derivative conversion | +100,000 | $2.32 | $232,000 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Alzamend Neuro Inc.
Who is the CEO of Alzamend Neuro Inc.?
Stephan Jackman is Alzamend Neuro Inc.'s Chief Executive Officer.
How many directors are on Alzamend Neuro Inc.'s board?
Alzamend Neuro Inc.'s board has 7 directors: Henry Carl Nisser, Jeffrey Oram, Lynne Fahey McGrath, Mark Gustafson, Milton C. Ault III, Stephan Jackman and William B. Horne.
Are Alzamend Neuro Inc. insiders buying or selling shares?
Over the last 12 months, Alzamend Neuro Inc. insiders bought $108,388 of shares in 1 purchase and sold $14,018 of shares in 3 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="alzamend-neuro-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.